August 25, 2025Scientific ReportsOpen Access

Lysionotin attenuates bleomycin-induced pulmonary fibrosis by activating AMPK/Nrf2 pathway

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Observational analysis shows lysionotin reduces myofibroblast differentiation in pulmonary fibrosis, indicating its therapeutic potential.

Lysionotin significantly reduces pulmonary fibrosis by activating the AMPK/Nrf2 pathway, enhancing antioxidant defenses.
In a mouse model, treatment with lysionotin diminished collagen deposition and myofibroblast activation after bleomycin exposure.
The study involved injecting lysionotin during established pulmonary fibrosis, emphasizing its effectiveness on oxidative stress modulation.
These findings support lysionotin's potential as a therapeutic agent against pulmonary fibrosis in human patients.

Zhang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational analysis shows lysionotin reduces myofibroblast differentiation in pulmonary fibrosis, indicating its therapeutic potential.